BLISS GVS PHARMA LTD.

11th February, 2016

To,
National Stock Exchange Ltd
Plot no. C/1 G Block,
Bandra-Kurla Complex,
BKC Road, Bandra (E),
Mumbai -400051

SUBJECT: BOARD MEETING OUTCOME

Dear Sir,

We like to inform you that the Board Meeting of the Company was held today i.e. on Thursday, 11th February, 2016 at the registered office of the company at 3.30 p.m. The Board has considered and approved the following:

1) Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the Unaudited Financial Quarterly and Nine months ended 31st December, 2015.

2) Limited Review Report for the Quarter and Nine months ended 31st December, 2015.

3) The Board has approved and take on record the recommendation of Nomination & Remuneration Committee at their Meeting held on 15th January, 2016 as follows-

   3.1) Mr. S.N. Kamath's tenure as Managing Director is extended by 3 years starting from 1st April, 2016 and annual salary of Rs. 1.5cr – 1.75cr – 2cr.

   3.2) Dr. Vibha Gagan Sharma's tenure as Wholetime Director is extended by 3 years starting from 27th January, 2016 and annual salary of Rs. 35lakh – 40lakh- 45lakh.

   3.3) Mrs. Shruti Vishal Rao's tenure as Wholetime Director is extended by 3 years starting from 1st April, 2016 and annual salary of Rs. 35lakh – 40lakh – 45lakh.

4) Mr. S. N. Kamath has been authorized to sign and execute the New Listing Agreement as per the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) with Stock Exchanges.

5) Pursuant to Regulation 30 (5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we provide hereunder the contact details of the authorized persons for the purpose of determining materiality of an event or information and for the purpose of making disclosures to Stock Exchanges:

BLISS GVS PHARMA LTD. MUMBAI

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.
TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771
Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. Palghar, Dist. Thane - 401 40
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

Name	Designation	Contact Details
Mr. S. N. Kamath	Managing Director	102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai-400072. Contact no.: 022-42160000 Email Id: md@blissgvs.com
Mr. Vipul Thakkar	Chief Financial Officer	102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai-400072. Contact no.: 022-42160000 Email Id: vipul.thakkar@blissgvs.com

6) The following Committees has been reconstituted-

6.1) **Audit Committee:**

Name of Member	Category	Status
Mr. Mayank Mehta	Independent Director	Chairman
Mr. S.R.Vaidya	Independent Director	Member
Mr. S.N. Kamath	Managing Director	Member

6.2) **Nomination & Remuneration Committee:**

Name of Member	Category	Status
Mr. S.R.Vaidya	Independent Director	Chairman
Mr. Mayank Mehta	Independent Director	Member
Mr. Gautam Ashra	Non Executive Director	Member

6.3) **Stakeholders Relationship Committee:**

Name of Member	Category	Status
Mr. Gautam Ashra	Non Executive Director	Chairman
Mr. Mayank Mehta	Independent Director	Member
Dr. Vibha Gagan Sharma	Wholetime Director	Member
Mrs. Shruti Vishal Rao	Wholetime Director	Member

Kindly acknowledged and take on record the same.

Thanking You,

For **BLISS GVS PHARMA LIMITED**

BLISS GVS PHARMA LTD. MUMBAI

VIPUL B. THAKKAR
CHIEF FINANCIAL OFFICER

BLISS GVS PHARMA LIMITED
Regd Office.102, Hyde Park, Sakivihar Road,
Andheri (East), Mumbai - 400 072
UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31.12.2015

(Rs.in Lacs)

SR. NO.	PARTICULARS	STANDALONE					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2015 (UNAUDITED)	30.09.2015 (UNAUDITED)	31.12.2014 (UNAUDITED)	31.12.2015 (UNAUDITED)	31.12.2014 (UNAUDITED)	31.03.2015 (AUDITED)
1	**INCOME FROM OPERATIONS**						
	(a) NET SALES (NET OF EXCISE DUTY)	8625.60	9268.54	8413.00	25876.97	24149.57	30945.89
	(b) OTHER OPERATING INCOME	61.08	97.97	168.29	201.10	287.77	356.28
	TOTAL INCOME FROM OPERATIONS(NET)	**8686.68**	**9366.51**	**8581.29**	**26078.07**	**24437.34**	**31302.17**
2	**EXPENSES**						
	a) CONSUMPTION OF RAW MATERIALS	3147.08	3715.49	4,041.61	10,346.44	10,837.80	13784.13
	b) PURCHASE OF TRADED GOODS	-	-	-	36.37	90.32	90.32
	c) CHANGES IN INVENTORIES OF FINISHED GOODS ,WORK IN PROGRESS, STOCK IN TRADE	(80.18)	(191.83)	(150.56)	(256.11)	135.17	248.27
	d) EMPLOYEE BENEFIT EXPENSES	579.64	564.07	454.39	1626.29	1266.71	1736.08
	e) DEPRECIATION / AMORTISATION	148.44	157.67	131.34	441.32	362.75	507.83
	f) OTHER EXPENDITURE	2469.76	2233.59	1791.28	6280.76	4783.86	6823.95
	TOTAL EXPENSES	**6264.74**	**6478.99**	**6268.06**	**18475.07**	**17476.62**	**23190.58**
3	**PROFIT FROM OPERATIONS BEFORE OTHER INCOME & FINANCE COST & EXCEPTIONAL ITEMS (1-2)**	**2421.94**	**2887.52**	**2313.23**	**7603.00**	**6960.73**	**8111.59**
4	OTHER INCOME	573.21	836.24	798.26	2040.24	1921.86	2135.03
5	**PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COST (3+4)**	**2995.16**	**3723.76**	**3111.49**	**9643.24**	**8882.59**	**10246.62**
6	FINANCE COST	298.43	416.24	349.61	1005.85	824.76	1121.18
7	**PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5-6)**	**2696.72**	**3307.52**	**2761.88**	**8637.39**	**8057.83**	**9125.44**
8	EXCEPTIONAL ITEMS	-	-	-	-	-	-
9	PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX (7 - 8)	2696.72	3307.52	2761.88	8637.39	8057.83	9125.44
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	559.80	891.28	962.62	2543.99	2702.39	3123.90
11	NET PROFIT AFTER TAX FOR THE PERIOD (9 - 10)	2136.92	2416.24	1799.26	6093.40	5355.44	6001.54
14	PAID - UP EQUITY CAPITAL	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)						35787.14
16	BASIC AND DILUTED EPS (NOT ANNUALISED) OF FACE VALUE OF RE. 1/- EACH	2.07	2.34	1.74	5.91	5.19	5.82

NOTES:-

1.THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.

2.THE ABOVE RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON FEBRUARY 11, 2016

3. THE TAX EXPENSE FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 30,2015 IS NET OF A REFUND OF RS. 217.66 LACS PERTAINING TO PRIOR YEARS, IN RESPECT OF WHICH A FAVOURABLE ORDER WAS RECEIVED BY THE COMPANY DURING THE QUARTER.

4. THE STATUTORY AUDITORS HAVE CARRIED OUT A LIMITED REVIEW OF THE RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2015

5.FIGURES FOR THE PREVIOUS PERIODS HAVE BEEN REGROUPED/REARRANGED WHEREVER NECESSARY.

FOR BLISS GVS PHARMA LTD

PLACE : MUMBAI
DATE : 11th February 2016

SD/-
S.N. KAMATH
MANAGING DIRECTOR

B. K. KHARE & CO.
CHARTERED ACCOUNTANTS

T + 91 022 22000607/7318/6360
+ 91 022 66315835/36
F + 91 022 2200 3476
E info@bkkhareco.com
706/708, Sharda Chambers New Marine Lines, Mumbai - 400 020, India

Limited Review Report

The Board of Directors
Bliss GVS Pharma Limited
Mumbai

We have reviewed the accompanying Statement of unaudited financial results of Bliss GVS Pharma Limited for the quarter ended December 31, 2015 ("the Statement"). This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410,"Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with the accounting standards specified under Section 133 of the Companies Act, 2013,read with rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

We draw attention to our reliance on management representation, in respect of the realisability of the Company's investment in and loan given to two of its subsidiaries (net of the amount realisable in on disposal of a step down subsidiary) aggregating Rs. 8,079 lakhs.

Our conclusion is not modified in respect of this matter.

For B. K. Khare & Co.
Chartered Accountants
Firm Registration No. 105102W

Himanshu Chapsey
Partner
Membership No. 105731
Mumbai, February 11, 2016

B. K. KHARE & CO. MUMBAI CHARTERED ACCOUNTANTS

Pune
T + 91 020 60601005/6/7/8/9
+ 91 020 25666932/32926341
E bkkpune@bkkhareco.com
Hotel Swaroop, 4th Floor,
Lane No.10, Prabhat Road,
Erandwane, Pune - 411 004, India

Bengaluru
T + 91 80 41105357
E bkkbengaluru@bkkhareco.com
101, Money Chambers,
1st Floor, # 6 K. H. Road,
Shanthinagar,
Bengaluru - 560027, India

New Delhi
T + 91 011 4905 7624
E bkkdelhi@bkkhareco.com
A - 4, Westend,
Rao Tula Ram Marg,
New Delhi - 110021.
India